Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Royal Bank of Canada (RY) Price & Performance

Alnylam Pharmaceuticals, Inc.Trade
Royal Bank of CanadaTrade

Price performance (Past 24H)

Key statistics

Alnylam Pharmaceuticals, Inc. vs Royal Bank of Canada — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $222.98 (market cap $29.60B), while Royal Bank of Canada trades at $210.44 (market cap $292.32B). The key difference: Royal Bank of Canada is far larger — about 9.9× Alnylam Pharmaceuticals, Inc.'s market cap, and Royal Bank of Canada pays a 2.37% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.

ALNYRY
Market Cap
$29.60B$292.32B
Sector
HealthFinancials
52-Week High
$491.22$217.87
52-Week Low
$205.48$134.80
Enterprise Value
$27.56B
Dividend Yield
2.37%

Returns comparison

Trailing returns across standard periods

About Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.

Read more on ALNY

About Royal Bank of Canada

Royal Bank of Canada is one of the two largest banks in Canada. It is a diversified financial services company, offering personal and commercial banking, wealth-management services, insurance, corporate banking, and capital markets services. The bank is concentrated in Canada, with additional operations in the U.S. and other countries.

Read more on RY